Home › NCT04233749

The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Subject age 18 and older
* Subject with a diagnosis of LPP, EDP, or AD
* Subject able to understand requirements of the study and risks involved
* Subject able to sign a consent form
* Subject to have discontinued all topical or oral medications, with the exception of sunscreen, used to treat pigmentary abnormalities one month prior to treatment

Exclusion Criteria:

* Personal history of clotting disorder or thromboembolic disease (deep vein thrombosis (DVT), stroke, etc)
* Active malignancy, excluding non-melanoma skin cancer
* Moderate to severe renal impairment
* History of migraine with aura
* Current anticoagulant therapy
* Current use of hormonal contraception or hormone replacement therapy in the last 30 days
* A woman who is lactating, pregnant, or planning to become pregnant

About the study

There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder. Given that LPP, EDP, and melasma are all disorders of pigmentation with dermal involvement, it is possible that tranexamic acid can also reduce pigmentation in LPP and EDP as well.

What is being tested

• Tranexamic acid tablets (drug)

Sponsor: Henry Ford Health System · Participants: 5 · Started: Mar 17, 2020

Contact the study team

• Angela Parks-Miller, RN · Phone: 1-313-916-0426
• Jennifer Creasor, RN · Phone: 1-313-916-0412

Official record on ClinicalTrials.gov — NCT04233749

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.